Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
For others, it means improving energy, mobility, or metabolic health while maintaining muscle
Patients in the UK will soon be able to buy the Wegovy weight-loss pill, the medicines regulator announced on Thursday
A pulmonary embolism is life-threatening and requires immediate medical attention
Cost Without Aetna Coverage Without insurance coverage, Ozempic can be expensive
If it looks cloudy, milky, or hazy, bacteria or fungi may be growing
